uridine monophosphate has been researched along with Mental Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abate, L; Amore, M; Cocito, L; Emberti Gialloreti, L; Guida, S; Krueger, F; Massucco, D; Mattei, C; Pardini, M; Sassos, D; Serrati, C | 1 |
| Haley, SJ; Kreek, MJ | 1 |
1 trial(s) available for uridine monophosphate and Mental Disorders
| Article | Year |
|---|---|
Souvenaid reduces behavioral deficits and improves social cognition skills in frontotemporal dementia: a proof-of-concept study.
Topics: Aged; Choline; Cognition; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Executive Function; Female; Folic Acid; Frontotemporal Dementia; Humans; Male; Mental Disorders; Middle Aged; Neuropsychological Tests; Outcome Assessment, Health Care; Selenium; Social Skills; Synapses; Treatment Outcome; Uridine Monophosphate | 2015 |
1 other study(ies) available for uridine monophosphate and Mental Disorders
| Article | Year |
|---|---|
A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act.
Topics: Adult; Antiviral Agents; Comorbidity; Drug Approval; Drug Therapy, Combination; Genotype; Health Services Accessibility; Hepatitis B; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Insurance Coverage; Mental Disorders; Patient Protection and Affordable Care Act; Population Surveillance; Poverty; Prevalence; Risk Factors; Simeprevir; Sofosbuvir; Substance Abuse, Intravenous; Sulfonamides; United States; Uridine Monophosphate | 2015 |